UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

Parvin Peddi, MD

Print
Email

Parvin Peddi, MD

UCLA Physician Parvin  Peddi, MD specializes in Hematology & Oncology.
Specialty
Hematology & Oncology
Gender
Female
Language Spoken
English, Farsi
Hospital Affiliation
Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
State License Number
A121192
Contact
(310) 829-5471 Santa Monica
(310) 325-8252 Torrance
Fax Number
(310) 829-6192 Santa Monica
(310) 325-8042 Torrance
Email Address
ppeddi@mednet.ucla.edu
PRACTICE LOCATION

UCLA Santa Monica Hematology Oncology
2020 Santa Monica Blvd, Suite 580
Santa Monica, CA 90404

ULCA Torrance Hematology Oncology
3445 Pacific Coast Hwy, Suite 300
Torrance, CA 90505

MEDICAL BOARD CERTIFICATION
Medical Oncology, American Board of Internal Medicine, 2013
Internal Medicine, American Board of Internal Medicine, 2009
EDUCATION
Fellowship
Hematology & Medical Oncology, UCLA School of Medicine, 2012 - 2013
Hematology & Medical Oncology, Washington University School of Medicine, 2010 - 2012
Residency
Chief Resident, Washington University School of Medicine, 2009 - 2010
Internal Medicine, Washington University School of Medicine, 2007 - 2009
Internship
Internal Medicine, Washington University School of Medicine, 2006 - 2007
Degree
MD, Duke University School of Medicine, 2006
CLINICAL INTEREST
Advanced Malignancies, Biliary, Brain Tumor, Breast Cancer, Cancers of the Digestive Tract, Chronic Myelogenous Leukemia, Colorectal (colon, rectum and anus), Esophageal Cancer, Gastric Cancer, Gastrointestinal Malignancies, General Oncology, Geriatric Breast Cancer, Gynecologic Oncology, Head and Neck Cancers, Hepatobiliary Cancers, Liver Cancer, Lung Cancer & Chest Malignancies, Lymphoma, Melanoma, Mesothelioma, Neuro Oncology, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Testicular Cancer, Thoracic Cancer, Unknown Primary
AFFILIATION
Department Affiliation
Provider, Hematology / Oncology, Breast Cancer Program
MORE INFORMATION
Research Interest
Breast Cancer, General Oncology/Hematology
Awards & Recognition
  • American Society of Clinical Oncology Young Investigator Award
  • Chief Editor of Washington Manual of Medical Therapeutics, 33rd Edition
  • Mentors in Medicine Research Award, Washington University School of Medicine
  • Howard–Hughes Medical Institute/NIH Scholar, Duke University School of Medicine
  • Phi Beta Kappa
  • Excellence in Research Award, Department of Biological Sciences, Vanderbilt University
Publications
  1. Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013 Feb 14;368(7):684-5.
  2. Peddi PF, Peddi S, Santos ES, Morgensztern D. Central nervous system toxicities of chemotherapeutic agents. Expert Rev Anticancer Ther. 2014 Jul;14(7):857-63.
  3. Peddi PF, Hurvitz SA. PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. J Neurooncol. 2014 Mar;117(1):7-13.
  4. Kasum M, Beketic-Oreškovic L, Peddi PF, Oreškovic S, Johnson RH. Fertility after breast cancer treatment. Eur J Obstet Gynecol Reprod Biol. 2014 Feb;173:13-8.
  5. Peddi PF , Cho M, Wang J, Gao F, Wang-Gillam A. Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. J Gastrointest Oncol. 2013 Dec;4(4):370-3.
  6. Wainberg ZA, Messersmith WA, Peddi PF , et al. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2013 Dec;12(4):248-54.
  7. Peddi PF , Shatsky RA, Hurvitz SA. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. Cancer Treat Rev. 2014 Mar;40(2):320-6.
  8. Cho M, Peddi PF, Ding K, et al. Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. J Transl Med. 2013 Sep 8;11:206.
  9. Peddi PF, Hurvitz SA. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol. 2013 Mar;9(3):319-26.
  10. Peddi PF, Wang-Gillam A. Successful resection after neoadjuvant therapy in pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1330-4.
  11. Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012 Sep 10;13(5):497-501.
  12. Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer. 2012;2012:217185.
Back to top
Referring a Patient to UCLA
Our staff will assist you in selecting the appropriate UCLA clinical department for your patient.

Find out how to refer a patient
Parvin Peddi, click here to update your profile.